Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-7: nemvaleukin alfa with pembrolizumab versus investigator's choice chemotherapy in platinum-resistant ovarian cancer
MOH_2022-11-30_012207Phase 3Not yet recruiting
- Sponsor
- Alkermes
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nemvaleukin alfa and pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Alkermes. Primary endpoint: Antitumor activity of nemvaleukin alfa + pembrolizumab versus chemotherapy. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
nemvaleukin alfapembrolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2022-11-30_012207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-30_012207.